Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Price Fixation: NPPA...

    Price Fixation: NPPA revises ceiling price of 8 IV fluids including Glucose; Details

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-02T11:45:40+05:30  |  Updated On 16 Aug 2021 5:05 PM IST

    NEW DELHI: Through a recent official release, National Pharmaceutical Pricing Authority (NPPA) has informed about the revision in the ceiling price of 8 IV fluids. The revision comes in order to take into account the inflation. As per the NPPA calculation, the new price has been determined after accounting for the Wholesale Price Index at the rate of 4.2662%. The new prices will take effect from April 1, 2019


    The formulations whose price has been fixed include Inj 5% Glucose 1000ml, Inj 5% Glucose 500 ml, Inj 0.9% sodium Chloride 100ml and 250ml


    Various manufacturers including B.Braun Medical (I) Pvt Ltd, Aculife Healthcare Pvt Ltd, Fresenius Kabi India Pvt Limited, Denis Chem Limited and others are impacted by the move.


    The details of the same reads;












































































    Sl NoMedicinesDosage form and StrengthUnitCeiling price (wef 1.4.2019 with WPI @ 4.2662%)
    (1)(2)(3)(4)(5)
    1GlucoseInjection 5%1000ml Non Glass with special features74.76
    2GlucoseInjection 5%500ml Non Glass with special features64.68
    3Glucose (A) + Sodium Chloride (B)Injection 5% (A) + 0.9% (B)1000ml Non Glass with special features78.56
    4Glucose (A) + Sodium Chloride (B)Injection 5% (A) + 0.9% (B)500ml Non Glass with special features67.22
    5Sodium ChlorideInjection 0.9%100ml Non Glass with special features33.06
    6Sodium ChlorideInjection 0.9%250ml Non Glass with special features48.82
    7Sodium ChlorideInjection 0.9%500ml Non Glass with

    special features
    69.13
    8Sodium ChlorideInjection 0.9%1000ml Non Glass with special features77.43

    The manufactured medicines are sold under the below -mentioned brand names;












































































    Sl. No.Name of ManufacturerProduct /Brand Name
    (1)(2)(3)
    1M/s B.Braun Medical (I) Pvt Ltd.Ecoflac Plus bottle with Eurohead
    2M/s Amanta Healthcare Ltd.Steriport bottle
    3M/s Aculife Healthcare Pvt Ltd.Aculife bottle with Eurohead
    4M/s Albert David LimitedAlbert David bottle with Eurohead
    5M/s Denis Chem LimitedAquapulse with Eurohead
    6M/s Claris Life Sciences LimitedClaris bottle with Eurohead
    7M/s Fresenius Kabi India Pvt LimitedFreeflex bags
    8M/s Otsuka Pharmaceutical India Private Ltd.

    (previously known as Claris Otsuka Private Limited)
    Unibag
    9M/s Aishwarya LifesciencesLifusion Eurohead bottle
    10M/s Baxter (India) Pvt. Ltd.Viaflex bags
    11M/s Otsuka Pharmaceutical India Private Ltd. (previously known as Claris Otsuka Private Limited)Eurohead bottle
    12M/s Fresenius Kabi India Pvt LimitedEurohead bottle

    The notice further adds;




    • The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if

    • The manufacturers of the above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing R.P. of their formulations, on the basis of WPI @ 4.2662% for year 2018 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.

    • The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said

    • Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack has all of the features as (i) self collapsibility and self-sealability (ii) not having air-vent; and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels along with documentation and

    • For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation

    • The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and

    • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the

    • Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO,

    • The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of

    • The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act,

    • Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


    Also Read: NPPA revises MRP of another 463 anti-cancer medicines; Check Details

    Aculife healthcareAlbert David Bottleceiling priceclaris Life sciencesEcoflac plusEuroheadglucosehealthhealth carehealth care newsinflationinjectionsmedicalmedical newsmedicinemedicinesNational Pharmaceutical Pricing AuthorityNon glass injectionNPPAprice fixationsodium chlorideWholesale Price IndexWPI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok